By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list - 2The Way to Recuperation: Defeating Dependence
- 3NMG signs new graphite supply deal with Canadian Government
- 4Blue Origin's next space tourism flight will break new ground for people with disabilities
- 5The Best Web-based Courses for Ability Advancement
- 'Heated Rivalry's Ilya Rozanov is now a queer icon in Russia
- 5 Critical Rules For Business Regulation Chiefs
- The Eastern Bongo, Kenya’s Rare Forest Antelope on the Brink
- What is IDF's view on pontential long-term occupation of southern Lebanon?
- David Duchovny's new thriller has him stripping down at 65. But its chilling premise hits close to home.
- 6 Web-based Lawful Administrations: Extensive Surveys and Elements
- Manageable Living: Eco-Accommodating Decisions for Regular day to day existence
- Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- FDA approves Wegovy pill for weight loss: What to know
